Primaquine

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Retrieved on: 
Wednesday, November 15, 2023
Medicine, Safety, Food, Type, Literature, Tafenoquine, Primaquine, Patient, FDA, Infection, Babesiosis, Malaria, Pharmaceutical industry

The meeting will take place on January 15, 2024.

Key Points: 
  • The meeting will take place on January 15, 2024.
  • Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA.
  • Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for such an indication.
  • The efficacy and safety of 8-aminoquinolines, a class of drugs that includes tafenoquine and primaquine, for prevention and treatment of malaria is well established.

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

Retrieved on: 
Thursday, October 19, 2023
FDA, ILADS, Literature, International Lyme and Associated Diseases Society, Malaria, Doctor of Philosophy, Poster, Tafenoquine, Primaquine, Medicine, Infection, Babesiosis, Safety, Pharmaceutical industry

The poster will be presented by 60 Degrees Pharmaceuticals Chief Executive Officer, Geoff Dow, PhD.

Key Points: 
  • The poster will be presented by 60 Degrees Pharmaceuticals Chief Executive Officer, Geoff Dow, PhD.
  • Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®.
  • The sponsored symposium will feature a comprehensive review of the use of 8-aminoquinolines in treating malaria and babesiosis.
  • The efficacy and safety of 8-aminoquinolines, a class of drugs that includes tafenoquine and primaquine, for prevention and treatment of malaria is well established.

Locally transmitted malaria in the US could be a harbinger of rising disease risk in a warming climate – 5 questions answered

Retrieved on: 
Friday, June 30, 2023
RTS, Vaccine, Infection, BioNTech, Disease, Pfizer, Headache, Travel, Conversation, Florida International University, Parasitism, Climate, Convulsion, Chills, Breeding, Myalgia, R21, Fever, World, Plasmodium, Temperature, Medicine, Florida Department, Artemisinin, Centers for Disease Control and Prevention, Plasmodium knowlesi, CDC, Death, Vivax, Protein, Climate change, Primaquine, Patient, Risk, Water, Bill, Weather, Center, Prevention, Plasmodium vivax, Skin, Consciousness, Female, Fatigue, Insecticide, Pharmaceutical industry, Agriculture, Tea, Malaria, Anopheles

The Centers for Disease Control and Prevention reported on June 26, 2023, that five cases of locally transmitted malaria had been identified – four in Florida and one in Texas – since May 2023.

Key Points: 
  • The Centers for Disease Control and Prevention reported on June 26, 2023, that five cases of locally transmitted malaria had been identified – four in Florida and one in Texas – since May 2023.
  • These are the first cases of locally acquired mosquito-borne malaria in the U.S. since 2003.

1. What is malaria and how did these people become infected?

    • Malaria is a serious and sometimes life-threatening disease caused by the bite of a female mosquito from the genus Anopheles, the vector that transmits malaria.
    • The most common symptoms are fever, chills, headaches, muscle aches and fatigue.
    • These symptoms typically occur from 10 to 15 days after people are infected with the parasite.

2. Why might these cases be surfacing now?

    • For one, climate change is causing a shift in weather patterns, some of which can worsen malaria conditions.
    • A higher average surface temperature from global warming could lead to higher mosquito migration in areas that were previously uninhabitable by Anopheles mosquitoes.
    • Given these changes in local conditions, more cases could occur in populations that were previously “immunologically naïve” to malaria.
    • This drives up the number of drug-resistant cases, the severity of the illness and the possibility of larger outbreaks.

3. How can people help prevent malaria transmission?

    • Precautions also include what’s known as “drain and cover” – in other words, draining standing water to prevent mosquitoes from multiplying and using screens to prevent mosquitoes from entering through doors and windows.
    • Health departments also note that it’s important to drain or discard containers that can collect rainwater, such as flower pots, old tires and buckets.

4. What are the available malaria treatments?

    • There are several medicines used to prevent and treat malaria.
    • The choice of medication typically depends on the type of malaria, whether a malaria parasite is resistant to a medicine, the weight or age of the person infected with malaria and whether the person is pregnant.
    • These kill malaria parasites by damaging their proteins and are usually the most effective treatment against malaria.

5. Are vaccines against malaria available?

    • Therefore, in October 2021, the World Health Organization began recommending the widespread use of a malaria vaccine known as RTS,S/ASOI for children who live in moderate- to high-risk areas.
    • Trials show that the vaccine can significantly reduce malaria, including severe malaria, among young children.
    • While new malaria vaccines will be a major boost for curbing malaria worldwide, it will be critical for health departments to continue emphasizing other preventive strategies, especially in newly affected areas like Florida and Texas.

The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)

Retrieved on: 
Friday, February 28, 2020
Infectious diseases, Chemical compounds, Quinolines, Medical specialties, RTT, Malaria, Primaquine, Plasmodium vivax, Antimalarial medication, Pamaquine, Tropical diseases, 8-Aminoquinoline

Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."

Key Points: 
  • Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."
  • [4] "Publicly-available data support a conclusion that tafenoquine shares the liability to CNS neurotoxicity of related 8-aminoquinolines," said Dr. Nevin.
  • Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist.
  • The effects of pentaquine,isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.